Member of the Austrian Drug Evaluation Committee (sick funds/reimbursement)
- Board of Austrian Pharmacological Society (APHAR)
- Task force Rare Disease Europa Bio and EBE
- Working Party Advanced Therapies
- July 2010 -2013: permanent industry representative EUCERD (EU Commission
- Working party for Rare Diseases
Cate Lockhart, MS, PharmD, PhD is the Program Director for the Biologics and Biosimilars Collective Intelligence Consortium (BBCIC.org) where she is responsible for both the business and research programs of this large, multi-stakeholder research collaboration.
Dr. Emile van Corven is Chief Development Officer at Bioceros. He has a track record of more than 27 years in the biopharmaceutical industry: global head of process development and pilot plant GMP manufacturing of MAbs and vaccines (Crucell/J&J), and the development or recombinant proteins (Pharming).
Fernanda Aleixo is specialist in Regulatory Affairs and member of the council of specialists of the National Association of Pharmacists.
Developed several activities with different stakeholders aiming to increase the education of the science behind the biosimilars medicines with the goal to share their value for the society, to increase the confidence on these health technologies, and to contribute for more rational and conscientious decisions.
Dr. Francois-Xavier Frapaise, M.D has over 35 years of international drug development, strategic planning and marketing experience at major pharmaceutical companies including Sanofi, Bayer, Boehringer, Merck and Abbott; he has hold multiple C-level positions (CSO,CMO,CEO) in different Pharmacos in the US and Europe.
Gillian Woollett, Senior Vice President, leads our FDA Practice. She provides the “prequel” of scientific and regulatory strategic policy expertise that supports medicinal products gaining approval at the FDA in a manner that allows them to be successful in the public and private reimbursement world. She is building a bridge for Avalere clients from the FDA space into the traditionally separate Centers for Medicare & Medicaid Services and healthcare policy/business world.
João Gonçalves is Head of the Biopharmaceutical Biotechnology Unit at the Institute of Innovative Medicines and Instituto de Medicina Molecular and Professor of Immunology and Biotechnology both part of the Faculty of Pharmacy, University of Lisbon, Portugal. He is also Head of Antibody Engineering Laboratory at iMed – Faculdade Farmacia Universidade Lisboa.
Dr. José Marona initiated Rheumatology residentship in 2016 at Hospital Egas Moniz – CHLO (Lisbon, Portugal). Since 2017 he is also a volunteer lecturer of Rheumatology in NOVA Medical School (Lisbon, Portugal) and a collaborator at the Center of Chronic Diseases from NOVA Medical School (CEDOC-NMS). He has participated in several clinical trials and research projects with particular focus on the impact of Biosimilars in the Portuguese market.
Professor Justin Stebbing at Imperial specialises in a range of malignancies, their treatment with biologics (breast, GI and lung and clinical trials), having originally trained in medicine at Trinity College Oxford, where he gained a first class degree. After completion of junior doctor posts in Oxford, he undertook training and a residency programme at The Johns Hopkins Hospital in the US, returning to London to continue his career in oncology at The Royal Marsden and then St Bartholomew’s Hospitals.
Lorraine Fincham is the Commercial Research Initiative Manager for the NIHR Clinical Research Network (CRN). Lorraine has worked actively as an academic researcher for several London Universities, working on prostate and bowel cancer studies after finishing her degree in Psychology and MSc in Health Psychology. She moved to the NIHR Clinical Research Network in 2007, firstly working locally in the North West London Diabetes Research Network as a Primary Care specialist before moving to the NIHR CRN Coordinating Centre in 2010.
Ned Pojskic is Green Shield Canada’s Leader for Pharmacy and Health Provider Relations. In this role, he is responsible for setting GSC’s strategic direction with respect to provider and drug benefits management. He takes the lead in managing stakeholder relations with all health care providers, including pharmacy, dental, and paramedical. Ned is also responsible for overall drug formulary management, including pricing and policy as well as pharmaceutical industry partnerships.
Graduated from University of Copenhagen (Medical Doctor) in 1994 and obtained a PhD-degree from University of Copenhagen with extensive technical studies at University of Pennsylvania in 1998.
Dr. Nikolai Brun practiced as a physician in the clinical field (Pediatrics) for a couple of years before continuing research and development work in the pharmaceutical industry especially working with biopharmaceuticals. Dr Brun has authored a long list of publications in high-impact journals.
Rahul Padhye has been working with Cipla since 2016 as Head BD& Licensing and recently he was assumed responsibility as Global Corporate Development Head.
Prior to this, he worked in Reliance Group for 20+ years in various business divisions such as petroleum marketing, infrastructure, alternative energy and life sciences.
In life sciences business, he was part of the Executive Management team and was responsible for heading global pharmaceuticals and biosimilars business divisions.
Rodeina Challand B.Sc., Director, Challand Biosimilar Consulting Ltd., Graduate from London University with over 25 years of experience in healthcare, cancer research and pharmaceutical industry across a wide range of roles including developing and implementing clinical development strategies for biosimilars at Hospira Inc. as Director of Clinical Projects and Head of Clinical Operations in the EU.
Roman Ivanov is Vice President, International business development, R&D, of biotechnology company BIOCAD, Dean of the Faculty of Molecular and Cell Biotechnology. He is responsible for product development and regulatory affairs.
Dr. Steinar Madsen is medical director at the Norwegian Medicines Agency. He has been working with generic substitution since it was introduced in Norway in 2001 and with biosimilars since 2006. He is member and previously chairman of the committee for generic substitution at the Agency. Dr. Madsen is also engaged in the drug information service, with a special interest in the safe and cost-effective use of drugs. He is a specialist in internal medicine and cardiology and works part time as a consultant in cardiology.
Suzette Kox was nominated Senior Director International in October 2015, following 14 years in the position of EGA’s Senior Director Scientific Affairs and Coordinator of the European Biosimilars Group (EBG), now Biosimilar Medicines Group, a sector group of Medicines for Europe (formerly EGA). She was the first Chairperson of the Biosimilars Committee of the International Generic and Biosimilar Medicines Association (IGBA).